The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes. Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas. For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant. GFAP, YKL-40, and ApoE reliably distinguished grade IIYIII oligodendrogliomas from grade IIYIV astrocytomas (p G 0.0001, p = 0.002, and p G 0.0001, respectively). Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas. In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.
INTRODUCTION
The histologic differential diagnosis of diffuse glioma remains subjective. As a result, the frequency with which a diagnosis of astrocytoma, oligodendroglioma, or oligoastrocytoma is made varies from one institution to another. Tumor cells may not always be easily recognized as either oligodendroglial or astrocytic, because they may have features of both lineages. In addition, the pronounced phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells, coupled with issues relating to sampling variability, complicates defining reliable diagnostic criteria (1) .
The recognition over the past decade that oligodendroglial tumors respond more dramatically to therapy and display a better prognosis than their astrocytic counterparts has placed even greater pressure on pathologists to make such diagnoses objective. The characteristic losses of chromosomal arms 1p and 19q in approximately 40% to 80% of oligodendrogliomas provide one objective diagnostic parameter. However, 1p and 19q losses are not present in all oligodendrogliomas but are found in modest percentages in oligoastrocytomas and in rare astrocytomas, thus limiting the diagnostic use of these genetic markers. There has therefore long been a desire for a specific immunohistochemical marker that could be used to reliably distinguish between oligodendroglial and astrocytic populations. Unfortunately, specific markers of mature oligodendrocytes such as myelin basic protein, myelin proteolipid protein, and myelinassociated glycoprotein are not highly expressed in oligodendroglial tumors (2, 3) . Potential novel markers could be found among factors known to be involved in central nervous system (CNS) development and normal gliogenesis such as the basic helix-loop-helix (bHLH) transcription factors Olig1/2, which play a major role in the specification of oligodendrocyte precursors during development and later persist in mature oligodendrocytes and progenitor cells (4Y6). Those factors held great promise as potential specific markers of oligodendroglial neoplasms but are now known to be highly expressed in all diffuse gliomas, reducing their promise as clinically useful markers (7Y11).
Oligoastrocytoma is defined as a tumor composed of a conspicuous mixture of 2 distinct neoplastic cell types that morphologically resemble the tumor cells of either oligodendroglioma or diffuse astrocytoma. Biphasic and intermingled variants are described. In the former, juxtaposed but distinct areas of oligodendroglial and astrocytic differentiation are present, whereas in the latter, both components are intimately admixed (1, 12) . We hypothesized that the biphasic variant of oligoastrocytoma would be optimal for comparative protein expression analysis of the 2 phenotypically distinct glial populations, because their presence within the same tumor would provide internal ''control'' for differences that might arise when comparing different oligodendrogliomas from astrocytomas.
For the present study, we selected candidate genes most relevant with regard to gliogenesis and putative glial lineage specificity. We then used immunohistochemistry to assess expression of the selected molecules (GFAP, YKL-40, ApoE, Olig2, Sox10, ASCL1, and NKX2-2) in the astrocytic and oligodendroglial components of biphasic oligoastrocytomas. Finally, to further evaluate the expression pattern of these potential tumor cell markers and directly address the issue of the diagnostic dilemma pathologists face in their routine practice, we investigated the expression of the most promising markers in ''pure'' oligodendroglial and astrocytic neoplasms.
MATERIALS AND METHODS

Tissue Samples
Tissue samples were selected from resection specimens in the Pathology Service, Massachusetts General Hospital (Boston, MA) after appropriate human studies permission was obtained. Fifty-five formalin-fixed, paraffin-embedded gliomas were studied: 8 biphasic oligoastrocytomas ( In initial experiments, a set of 8 biphasic oligoastrocytomas were selected by 2 neuropathologists (AR and DNL) based on the presence within the tumor of juxtaposed but distinct areas of oligodendroglial and astrocytic differentiation (1) . Subsequently, an additional 21 oligodendrogliomas, 21 astrocytomas, and 5 glioblastomas were selected for immunohistochemistry and stained with the antibodies found to be most relevant in the initial biphasic oligoastrocytoma experiments. Diagnosis and grading of the tumors were based on the 2000 WHO classification of brain tumors (13) . All studied tumors were considered to be histologically classic and were therefore agreed on by the 2 neuropathologists. Of note, tumors with numerous microgemistocytes were not included, because they tended to be less ''classic'' and because the relationship of these cells to frank astrocytic gemistocytes is not clear, but microgemistocytes were included in the scoring. All oligodendrogliomas had been selected after genetic study to assess 1p and 19q status with either fluorescence in situ hybridization or loss of heterozygosity studies; all studied oligodendrogliomas had allelic losses of 1p and 19q (data not shown).
Immunohistochemistry
Immunohistochemistry was performed on 5-Km serial sections that were mounted on charged glass slides and baked at 60-C overnight. The slides were deparaffinized with xylene and treated with 0.5% hydrogen peroxide in methanol for 10 minutes at room temperature. Sections were rehydrated and washed with phosphate-buffered saline (PBS) followed by antigen retrieval with 10 mmol/L sodium citrate buffer (pH 6) in a microwave oven for 20 minutes. For ApoE and YKL-40 immunostaining, antigen retrieval was achieved with a 5-minute incubation in 0.05% saponin/ 1% bovine serum albumin (BSA)/PBS solution. GFAP immunohistochemistry was done in the absence of antigen retrieval. After blocking with 10% normal goat or horse serum in PBS/1% BSA for 30 minutes at room temperature, the sections were incubated overnight at 4-C with the specific primary antibodies. Primary monoclonal (M) or polyclonal (P) antibodies (source and dilution stated in parentheses) against the following antigens were used: GFAP (Dako, Carpinteria, CA; 1:1,000, mouse M); YKL-40 (Quidel Corp., San Diego, CA; 1:200, rabbit P); apolipoprotein E (ApoE) (Chemicon, Temecula, CA; 1:8,000, goat P); Olig2 (DF138; 1:20,000, rabbit P); ASCL1 (BD Biosciences, San Jose, CA; 1:200, mouse M); Sox10 (Cemines, Golden, CO; 1:200, rabbit P); and NKX2-2 (Developmental Studies Hybridoma Bank, Iowa City, IA; 1:25, mouse M). On the next day, appropriate biotinylated IgG secondary antibodies (Vector, Burlingame, CA) were applied for 30 minutes at room temperature followed by detection of immunoreactivity with an avidinYbiotin system (Vector) using 3,3 ¶-diaminobenzidine tetrahydrochloride as a chromogen. Sections were lightly counterstained with Mayer's hematoxylin (Richard-Allan Scientific, Kalamazoo, MI). Normal brain parenchyma from a 25-week-old fetus served as control tissue for Olig2, Sox10, ASCL1, and NKX2-2 immunohistochemistry, and adult brain parenchyma with reactive gliosis was used for GFAP, YKL-40, and ApoE immunostaining. Negative controls without primary antibodies were performed for all reactions. The controls were run under the same conditions as those applied when using the respective primary antibodies.
Antigen expression levels were assessed based on the percentage of positively stained tumor cells. Neoplastic cells were distinguished from nonneoplastic cells so that only tumor cells were scored. Numeric scores were then assigned as follows as a percentage of positive tumor cells over the total number of tumor cells: 0 (G5% positive tumor cells), 1 (5Y25%), 2 (25Y50%), 3 (50Y75%), and 4 (>75%). Positively stained blood vessels were not included in the scoring.
Statistical Analyses
A permutation based Wilcoxon signed rank test was used to compare expression levels in the oligodendroglial and astrocytic components within individual oligoastrocytomas. To compare marker expression in oligodendroglioma versus astrocytoma, permutation-based Wilcoxon rank sum tests were applied. Permutation-based Kruskal-Wallis tests were used to compare marker expression across astrocytic tumor grades (WHO grade IIYIV). For all permutation tests, 10,000 draws were made from the permutation distribution. A Bonferroni correction was applied to each of the 3 primary hypothesis tests to adjust for the multiple testing within each of those hypotheses; adjusted p values are reported. The primary hypothesis tests concerned: 1) comparison of oligodendroglial versus astrocytic components within individual oligoastrocytomas (6 subhypothesis tests); 2) comparison of oligodendrogliomas versus astrocytomas (19 subhypothesis tests); and 3) comparison of YKL-40 among astrocytic tumor grades (3 subhypothesis tests). All tests were 2-sided and the overall significance level for each of the 3 primary hypotheses was taken to be 0.05.
RESULTS
Immunohistochemical Markers for Distinguishing Between Oligodendroglial and Astrocytic Components Within Individual Biphasic Oligoastrocytomas
When comparing marker expression between the oligodendroglial and astrocytic components within individual oligoastrocytomas, only GFAP expression was significantly different (p = 0.044) ( Fig. 1 ; Table 1 ). In our series, all astrocytic components displayed a GFAP expression score greater than or equal to 2, whereas all oligodendroglial components had a score less than or equal to 1. Although none of the other markers tested showed a statistically significant difference in their expression levels between the 2 tumor components, there was a trend toward higher expression levels of YKL-40 and ApoE in the astrocytic component of individual oligoastrocytomas compared with the oligodendroglial component. In fact, YKL-40 expression was detected in more than 25% tumor cells in 5 of 8 individual astrocytic components, whereas 7 of 8 oligodendroglial components displayed less than 5% immunopositive tumor cells. Regarding ApoE expression, 7 of 8 astrocytic components were comprised of more than 25% immunopositive tumor cells, whereas the protein was not detected in 5 of 8 oligodendroglial components. Finally, slightly higher expression levels of Olig2, ASCL1, and NKX2-2 markers were observed in the oligodendroglial population compared with the astrocytic component within individual oligoastrocytomas (Table 2) . High expression levels of Sox10 were detected across both tumor components.
GFAP, YKL-40, and ApoE Expression Differentiates Between Oligodendroglial and Astrocytic Neoplasms
When comparing grade IIYIV astrocytomas versus grade IIYIII oligodendrogliomas for the expression of the most promising molecular markers (i.e. GFAP, YKL-40, ApoE, Olig2, ASCL1, and NKX2-2), GFAP, YKL-40, and ApoE staining was significantly different (p G 0.0001, p = 0.002, and p G 0.0001, respectively) ( Figs. 1 and 2 ; Table 1 ). Seventeen of 21 (81%) oligodendrogliomas had no immunostaining for GFAP, whereas the protein was detected in all 26 astrocytomas with 15 lesions (58%) having at least 50% positive tumor cells. YKL-40 protein was undetectable in oligodendrogliomas but was expressed in 13 of 26 (50%) astrocytomas, 12 (92%) of the immunostained gliomas being high-grade tumors. None of the 21 oligodendrogliomas expressed ApoE, whereas the protein was present in all astrocytomas except one, although in less than 50% tumor cells in most cases. Similar results were obtained when comparing anaplastic oligodendrogliomas versus glioblastomas. GFAP, YKL-40, and ApoE expression levels were all significantly different (p = 0.01, 0.01, and 0.002, respectively). ASCL1 and NKX2-2 expression was also significantly different between grade IIYIV astrocytomas and grade IIYIII oligodendrogliomas (p = 0.017 and 0.004, respectively) ( Fig. 1 ; Table 2 ). Twenty-four of 26 (92%) astrocytomas were either immunonegative or comprised of less than 25% ASCL1-expressing tumor cells. Conversely, 11 of 21 (52%) oligodendrogliomas presented at least 25% positive tumor cells with 5 lesions displaying more than 50% positive cells. For NKX2-2 staining, 21 of 26 (80%) astrocytomas were either immunonegative or comprised of less than 25% expressing tumor cells. In contrast, 16 of 21 (76%) oligodendrogliomas had at least 25% immunostained cells and 9 (56%) of those neoplasms contained more than 50% NKX2-2-expressing tumor cells. Differences in Olig2 expression were not significant (see ''Discussion'').
Immunohistochemical Markers in Grade II and Grade III Astrocytomas and Oligodendrogliomas
We next compared the expression of the putative lineage markers in grade IIYIII astrocytomas versus grade IIYIII oligodendrogliomas (i.e. in nonglioblastoma diffuse gliomas, because this is a common diagnostic issue). GFAP, YKL-40, and ApoE staining was also significantly different (p G 0.0001, p = 0.038, and p G 0.0001, respectively) between astrocytomas and oligodendrogliomas. For the oligodendroglial lineage markers, NKX2-2 expression varied significantly between the glioma subtypes (p = 0.002). Differences in ASCL1 expression levels between astrocytomas and oligodendrogliomas almost reached statistical significance with a p value of 0.057. Again, differences in Olig2 expression were not significant (see ''Discussion'').
DISCUSSION
We compared expression of a panel of glial lineage markers between the 2 distinct glial populations (i.e. oligodendroglial and astrocytic) of biphasic oligoastrocytomas and a series of astrocytic and oligodendroglial gliomas. We demonstrated that expression of a number of the molecules studied can provide information relevant to glioma classification. In addition to GFAP, 2 of these proteinsVYKL-40 and ApoEVappeared promising as astrocytoma markers and 2 othersVASCL1 and NKX2-2Vwere potential markers of oligodendroglial tumor cells. . Top of box is 75th percentile, bottom is 25th percentile, whiskers are data points not more than 75th percentile + 1.5* interquartile range (IQR) and not less than 25th percentile Y 1.5 * IQR. Note that GFAP, YKL-40, and ApoE expression is detected in astrocytomas but not in oligodendrogliomas (bold lines positioned at the medians for the latter). ASCL1 and NKX2-2 expression is higher in oligodendrogliomas compared with astrocytomas, whereas no difference is observed for the Olig2 marker. Copyright @ 2006 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
In the present study, YKL-40 expression showed a trend toward higher levels in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part. More significantly, YKL-40 reliably distinguished between astrocytic tumors and ''pure'' oligodendrogliomas with clearly higher expression in astrocytomas. YKL-40 is a secreted molecule that may play a role in tissue degradation and remodeling of the extracellular matrix (14, 15) . YKL-40 is also a growth factor for vascular endothelial cells and fibroblasts, and functions as an adhesion and migration factor for vascular smooth muscle and endothelial cells, therefore supporting angiogenesis (16, 17) . High serum levels of YKL-40 have been detected in various cancers such as breast, colon, and ovarian carcinomas, and such elevated levels have been associated with aggressive clinical course, notably metastatic disease, and poor prognosis (18Y22). Hence, through extracellular matrix alteration and proliferative activity, YKL-40 may contribute to tumor invasion, cell migration, and angiogenesis.
YKL-40 is highly overexpressed in glioblastoma (23Y27). In a recent gene expression-based microarray analysis, we identified YKL-40 as having an average expression level in glioblastomas 82-fold greater than the average expression found in anaplastic oligodendrogliomas (28) . In a separate study, we demonstrated significantly higher YKL-40 protein expression as assessed by immunohistochemistry in glioblastomas compared with anaplastic oligodendrogliomas (27) . The present study extends those findings to include lower-grade neoplasms as well. The analysis, however, is complicated by the fact that YKL-40 expression increases with malignancy grade (24, 25) . Our results are in agreement with these studies because YKL-40 expression varied significantly across the WHO grades of astrocytoma with little staining in grade II tumors (p G 0.0001; data not shown). A relationship with grade was also suggested in our studied oligoastrocytomas in which the astrocytic component of the 2 low-grade oligoastrocytomas displayed either no immunoreactivity for YKL-40 or less than 25% positive tumor cells, whereas all but one anaplastic oligoastrocytoma had more than 25% positive tumor cells and half of the anaplastic oligoastrocytomas were comprised of more than 50% YKL-40 expressing cells. Interestingly, the single low-grade oligoastrocytoma that had an YKL-40 expression score of 1 had some anaplastic features. As a result of YKL-40 being more diffusely expressed in highergrade astrocytomas, its staining pattern was not significantly different between grade II oligodendrogliomas and grade II astrocytomas but varied significantly between grade III anaplastic oligodendrogliomas and grade III anaplastic astrocytomas (p = 0.034; data not shown). Assessing YKL-40 expression may thus be a useful diagnostic tool to distinguish between higher-grade diffuse gliomas.
Increased expression of YKL-40 has been associated with poorer response to radiation therapy, as well as shorter progression-free and overall survival time, in glioblastoma (29) . Interestingly, YKL-40 is one of the genes associated with malignant glioma recurrence and with a shift toward a ''mesenchymal'' gene expression pattern (30) . This expression signature was also notable for robust expression of angiogenesis markers such as vascular endothelial growth factor (VEGF) and its receptors. In our study, YKL-40-expressing tumor cells were preferentially located in the close vicinity of blood vessels, and it is therefore tempting to speculate that increasing YKL-40 expression in the progression from low-grade to high-grade astrocytomas may parallel the development of angiogenesis.
ApoE demonstrated prominent expression in astrocytic tumor cells and appears to be a practical astrocytoma marker. ApoE is a key determinant in the transport and metabolism of cholesterol and phospholipids. It is primarily synthesized in the liver, but ApoE mRNA is particularly abundant in the brain, notably in astrocytes (31Y33). Normal astrocytes display strong cytoplasmic immunostaining for ApoE, whereas neurons, oligodendrocytes, ependymal cells, and choroid plexus are immunonegative (32, 34) . Interestingly, ApoE is not expressed by myelinating cells of the central and peripheral nervous system (i.e. oligodendrocytes and myelinating Schwann cells) (32, 35) . Although the primary function of ApoE is lipid transport, recent data have suggested additional roles for the protein in brain homeostasis and regulation of astrocytic and neuronal functions, including neurotransmission, growth factor release, and immune responses (36) . Moreover, ApoE expression is dramatically upregulated in response to injury to the central and peripheral nervous system, again, notably, in activated astrocytes (37) . It has even been suggested that ApoE might be a more reliable marker of astrocytes and their specialized counterparts (e.g. Bergmann glia, tanycytes, pituicytes, and Müller cells) than GFAP because of the consistent distribution of ApoE compared with the more variable expression of GFAP in those cells (32, 35) .
In another study, ApoE expression was studied in 77 intracranial neoplasms, including 42 gliomas; marked cytoplasmic staining was found in grade I to III astrocytomas as well as lesser positivity in glioblastomas (34) . Immunopositive tumor cells were also observed in the astrocytic component of mixed oligoastrocytomas, in medulloblastomas with glial differentiation (as assessed by GFAP expression), as well as in rare ependymomas. Conversely, no immunoreactivity for ApoE was detected in oligodendroglioma, choroid plexus papilloma, hemangioblastoma, primary malignant lymphoma, neurinoma, meningioma, pituitary adenoma, and craniopharyngioma (34) . ApoE expression has also been reported in 12 glioblastoma cases (38) . Given that GFAP staining may be variable in astrocytic tumors, particularly in high-grade neoplasms such as glioblastoma, the present results are notable because ApoE appeared at times more dependable compared with GFAP; some oligodendroglioma cases expressed GFAP but were completely immunonegative for ApoE. Assessing ApoE expression along with GFAP immunoreactivity may thus help identify the nature of the tumor cells in diagnostically challenging gliomas.
We assessed the expression level of several key transcription factors (i.e. Olig2, Sox10, ASCL1, and NKX2-2) involved in CNS development, especially in gliogenesis. The present study is the first to analyze ASCL1 and NKX2-2 expression immunohistochemically in human brain tumors; notably, expression of ASCL1 and NKX2-2 correlated with the oligodendroglial phenotype. ASCL1 is a proneural bHLH transcription factor transiently expressed during CNS development. ASCL1 is required for the specification of both neuronal and oligodendrocyte precursors in the subventricular zone, and a decrease in or absence of ASCL1 expression leads to a defect in oligodendrogliogenesis as well as to progenitor commitment to an astrocytic fate (39) . NKX2-2 is a transcription factor that plays an essential role in the differentiation and/or maturation of oligodendroglial progenitors but not in their initial specification. It interacts with Olig2 at late developmental stages to promote oligodendrocyte maturation to the myelin basic protein-expressing stage (40Y42). Although ASCL1 and NKX2-2, therefore, appear promising oligodendroglial tumor cell markers, a certain degree of overlap in expression levels was observed between oligodendrogliomas and astrocytomas, and further studies are needed to evaluate ASCL1 and NKX2-2 expression in a larger series of gliomas.
Olig1/2 transcription factors are a set of bHLH proteins that regulate neural cell fate decisions during development, particularly oligodendrogliogenesis (4Y6). The present data on Olig2 expression agree with those of our prior study in which we observed diffuse expression in both oligodendroglial and astrocytic tumors, albeit with oligodendrogliomas showing more extensive positivity and astrocytomas being typically characterized by heterogeneous levels of Olig2 expression (11) . Because Olig2 expression had been the subject of this previous report, we only studied Olig2 expression in 4 grade II oligodendrogliomas, 5 grade III anaplastic oligodendrogliomas, 5 grade II astrocytomas, 4 grade III anaplastic astrocytomas, and 5 glioblastomas. In this small series, strong diffuse staining was noted in all oligodendrogliomas and all grade II astrocytomas, whereas less consistently high staining was found in the higher-grade astrocytomas, particularly in the 5 glioblastomas (scores of 1, 1, 2, 2, and 2). To further evaluate the possible use of using a higher cutoff value for Olig2 staining, we also determined whether using a score of >90% staining more reliably distinguished oligodendrogliomas. Nearly all cases scored as >75% staining had >90% positivity and neither cutoff value generated statistically significant differences between all oligodendrogliomas and astrocytic tumors based on a stringent Bonferroni-adjusted significance level. Nonetheless, it was our subjective impression that the extent of Olig2 expression could be used to distinguish high-grade oligodendrogliomas, which nearly all show extensive staining, from glioblastomas, which typically show less than 50% positivity. However, given the relatively small number of cases studied for Olig2 and the number of comparisons tested in our analyses, the Bonferroni-adjusted p values were not significant. Further study of larger numbers of highgrade oligodendrogliomas and glioblastomas is suggested to further evaluate this question.
Sox proteins are developmentally regulated transcription factors characterized by the presence of a highly conserved DNA-binding HMG (high mobility group) domain (43) . Sox group E members, Sox8, Sox9, and Sox10, regulate development of myelin-producing cells in both the central and peripheral nervous systems (44Y46). In the CNS, Sox10 is restricted to late stages of oligodendroglial development (46) . The protein has been reported to be ubiquitous in human gliomas (47) . In the present study, Sox10 was diffusely expressed in both oligodendroglial and astrocytic neoplasms. Because the Sox10 gene and protein sequence are highly homologous to those of other Sox group E members (i.e. Sox8 and Sox9), including at the epitope used to generate the anti-Sox10 antibody that we used in this study, there may be some degree of crossreactivity to other Sox group E proteins. As a result, the observed lack of difference between astrocytomas and oligodendrogliomas may be germane to group E as a whole. Although such a diffuse expression of Sox10 protein in both tumor types clearly undermines any potential for differential diagnostic use among gliomas, the expression of this developmentally regulated transcription factor may hint at the likely stem cell or progenitor cell nature of malignant gliomas (48) . In this regard, it is interesting to note that Sox2, which is one of the earliest transcription factors detected in CNS development (KLL, AR, DNL, DHR, unpublished data), was widely and intensely expressed in both glial populations (KLL, AR, DNL, DHR, unpublished data).
In summary, we identified immunohistochemical markers that might be useful in clinical practice to distinguish oligodendrogliomas from astrocytomas. Assessment of YKL-40 and ApoE protein expression provides information relevant to glioma classification, indicating astrocytic tumor cells. In addition, YKL-40 expression may predict aggressive behavior in astrocytomas. Furthermore, ASCL1 and NKX2-2 transcription factors may be potential markers of oligodendroglial tumor cells. Future studies will be needed to further characterize these markers and to determine if their clinical assessment will be a valuable adjunct for diagnosis. Finally, it is relevant to note that diffuse expression of some putative lineage-restricted molecules (e.g. Sox10 protein) in both oligodendrogliomas and astrocytomas supports the presumed origin of gliomas from progenitor cells. Such a mixed expression pattern also highlights that a cell type may be best defined by a combination of markers. Nonetheless, tumor cell differentiation may not always correlate with expression of specific lineage markers and morphology may be less related to cell lineages than to signaling pathways involved in tumorigenesis (49Y51). Ultimately, tumor cell phenotype may be determined by both molecular alterations in specific signaling pathways and the nature of the initiating cell.
